

**CAMB 605 Course Syllabus (Fall 2024)**

Tuesdays 1:45-3:15p  
September 3 – December 10, 2023

**Course Director:** Matt Good ([mattgood@penncmedicine.upenn.edu](mailto:mattgood@penncmedicine.upenn.edu)), 1151 BRB

**Paper Presentation Schedule****9/3. CAMB 605 Course Overview**

**9/10. MVP.** Blood culture-free ultra-rapid antimicrobial susceptibility testing  
*Nature* 2024. <https://pubmed.ncbi.nlm.nih.gov/39048820/>

**9/17. G&E.** RNA damage compartmentalization by DHX9 stress granules  
*Cell* 2024. <https://pubmed.ncbi.nlm.nih.gov/38503283/>

**9/24. CPM.** An airway-to-brain sensory pathway mediates influenza-induced sickness  
*Nature* 2023. <https://pubmed.ncbi.nlm.nih.gov/36890237/>

**10/1. GTV.** Engineered CD47 protects T cells for enhanced antitumour immunity  
*Nature* 2024. <https://pubmed.ncbi.nlm.nih.gov/38750365/>

**10/8. DSRB.** Airway hillocks are injury-resistant reservoirs of unique plastic stem cells  
*Nature* 2024. <https://pubmed.ncbi.nlm.nih.gov/38693267/>

**10/15. CB.** Early clonal extinction in glioblastoma progression revealed by genetic barcoding  
*Cancer Cell* 2023. <https://pubmed.ncbi.nlm.nih.gov/37541243/>

**10/22 – No CAMB 605 class**

**10/29. MVP.** Pathogen-driven CRISPR screens identify TREX1 as a regulator of DNA self-sensing...  
*Cell Host & Microbe* 2023. <https://pubmed.ncbi.nlm.nih.gov/37652009/>

**11/5. G&E.** Autonomous transposons tune their sequences to ensure somatic suppression  
*Nature* 2024. <https://pubmed.ncbi.nlm.nih.gov/38355802/>

**11/12. CPM.** CLSTN3 $\beta$  enforces adipocyte multilocularity to facilitate lipid utilization  
*Nature* 2023. <https://pubmed.ncbi.nlm.nih.gov/36477540/>

**11/19. GTV.** Naturally occurring T cell mutations enhance engineered T cell therapies  
*Nature* 2024. <https://pubmed.ncbi.nlm.nih.gov/38326614/>

**11/26 – No CAMB 605 class**

**12/3. DSRB.** Cell-type-directed design of synthetic enhancers  
*Nature* 2024. <https://pubmed.ncbi.nlm.nih.gov/38086419/>

**12/10. CB.** CD8+ T cells maintain killing of MHC-I-negative tumor cells through NKG2D-NKG2DL axis  
*Nature Cancer* 2023. <https://pubmed.ncbi.nlm.nih.gov/37537301/>